Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
复制标题
DOI：
10.18632/oncotarget.6690
复制
发表时间：
2016-02-16
期刊：
影响因子：
--
通讯作者：
Lin WJ
中科院分区：
文献类型：
--
作者：
Izumi K;Mizokami A;Lin HP;Ho HM;Iwamoto H;Maolake A;Natsagdorj A;Kitagawa Y;Kadono Y;Miyamoto H;Huang CK;Namiki M;Lin WJ
前列腺特异性抗原（PSA）被认为是前列腺癌最敏感的生物标志物。虽然雄激素/雄激素受体（AR）信号传导促进前列腺癌进展，但AR信号传导的抑制诱导趋化因子（CC基序）配体2（CCL 2），其使前列腺癌细胞获得转移潜能。对于接受雄激素剥夺治疗的患者，单独使用AR控制的PSA可能是不可靠的生物标志物。因此，我们研究了CCL 2作为PSA的补充生物标志物用于前列腺癌的有效性。我们富集具有较高迁移潜力的前列腺癌细胞的体外方法表明，CCL 2激活了细胞迁移。重要的是，我们发现CCL 2水平在患有和不患有前列腺癌的男性（n = 379）之间存在显著差异。与CCL 2 <320 pg/mL的患者相比，CCL 2 ≥ 320 pg/mL的患者的总生存期和前列腺癌特异性生存期更差。根据风险因素CCL 2 ≥ 320 pg/mL和PSA ≥ 100 ng/mL开发了一种新的风险分类，评分2、1和0分别定义为不良、中度和良好风险，并明确区分患者结局。CCL 2可能作为前列腺癌的一种新的生物标志物。基于CCL 2和PSA组合的新风险分类比单独使用任何一种更可靠。
Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 < 320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.